Below is an English translation of the decision, provided by MLex. The original decision in Chinese can be found here.Simcere Pharmaceutical fined by China’s SAMR for abuse of dominanceInvestigative proceduresIn accordance with China’s Antimonopoly Law, the State Administration for Market Regulation (SAMR) initiated an investigation of Simcere Pharmaceutical Group in September 2020